Page 1660 - Clinical Small Animal Internal Medicine

1598 Index

cytology (cont’d) feline 1452–1454 therapeutic plan and client
VetBooks.ir liver disease 655–656 treatment and prognosis topical therapy 1397–1399
history and clinical signs 1449–1451,
education 1396
lymphoid leukemias 1224,
1450–1451, 1453, 1453
treatment trials 1394
1224–1225
lymphomas 1232 1451–1452, 1453–1454 see also individual conditions/agents
mammary cancer 1322 demyelinating leukoencephalomyelitis dermatomyositis (DM) 1423, 1424
mast cell tumors 1359–1360, 1360, (DL) 851–852 dermatophytosis 987–988
1365–1366 dentigerous cysts 539 approach to the dermatologic
meningoencephalitis and deranged nitrogen metabolism 714 patient 1393–1394
meningomyelitis 798–799 Dermanyssus gallinae 1458–1459 diagnosis 987
miscellaneous skin diseases diagnosis 1459 epidemiology and signalment 987
1496, 1504 etiology/pathophysiology 1458 etiology/pathophysiology 987
mycobacteriosis 982, 982 history and clinical signs 1458 history and clinical signs 987, 987
nonmelanoma skin cancers 1355 treatment and prognosis 1459 public health implications 988
otitis externa 1474, 1474–1475, dermatologic disease treatment and prognosis 988
1475, 1476 antibacterial agents 1400–1401 descriptive statistics 10–12, 11–13
pancreatitis 596–597 antifungal agents 1401 detrusor atony 1186
pleural effusion 340, 340, antiinflammatory agents detrusor hyperreflexia 1186
342, 342 1399–1400 detrusor urethral dyssynergy
prostatic diseases 1159, 1160, 1162 antiparasitic agents 1401–1402 (DUD) 1186–1187
protozoal and arthropod‐borne antipruritic agents 1400 developmental orthopedic diseases
infections 839–841 approach to the dermatologic (DOD) 1537–1551
protozoal and protozoa‐like patient 1375–1396 breed dispositions 1538
infections 1009 biopsy and histopathology canine hip dysplasia 1534–1540
rectoanal diseases 609 1394–1396 craniomandibular
viral infections 843 categories and indications for osteopathy 1548–1549
yersiniosis 953 therapeutic approach 1399–1402 elbow dysplasia 1542–1544
cytoscopic‐guided basket common formulations of topical hypertrophic osteodystrophy
removal 1147 agents 1397–1399 1549–1550
cytoscopy 1183 cutaneous manifestations of systemic Legg–Calvé–Perthes disease
cytotoxic T lymphocytes (CTL) 1568 disease 1481–1490 1547–1548
diagnostic tests and osteochondrosis 1540–1542, 1541
d techniques 1383–1396 osteochondrosis dissecans of the
DAG see diacylglycerol distribution of lesions 1383, hock joint 1544–1545
Darrow–Yannet diagram 1388–1391 osteochondrosis dissecans of the
1069–1070, 1070 epidemiology 1375 shoulder joint 1542
DC cardioversion 217–218 history and clinical signs osteochondrosis dissecans of the
DCM2 mutation 253, 259 1375–1381, 1396 stifle joint 1544
D‐dimers 315, 316 immunosuppressive agents 1400 panosteitis 1549
debridement 1031 miscellaneous skin patella luxation 1546–1547
defibrillation 369–370, 419–420 diseases 1495–1506 retained cartilaginous
degenerative myelopathy (DM) 820 morphology of lesions 1382, core 1545–1546
dehydration see hydration and 1382–1383, 1383–1387 slipped capital femoral
dehydration; sodium and water physical examination 1381–1383 epiphysis 1550–1551
homeostasis principles of therapy of dermatologic DEXA see dual‐energy X‐ray
delayed gastric emptying 567 diseases absorptiometry
delayed resuscitation 361 1397–1402 dexamethasone suppression testing see
demodicosis 1449–1454 pruritus 1376 high‐dose dexamethasone
approach to the dermatologic screening tests 1385–1394 suppression; low‐dose
patient 1376, 1392–1393 signalment 1375–1376, 1377–1381 dexamethasone suppression
canine 1449–1452 systemic medications for hormonal dextrans 359
diagnosis 1451, 1453 disorders 1402 DFA see direct fluorescent antibody
etiology/pathophysiology 1449, systemic therapy 1399 DGGR‐based lipase activity 593,
1450, 1452–1453 tests of noncutaneous organs 1396 604–605, 608